

Special Issue

Signaling Pathways and Immune-Checkpoint Regulation in Cancers

Message from the Guest Editor

Seeking better knowledge of signaling pathways involved in immune-checkpoint regulation might help to overcome arising issues and improve the overall benefits of this revolutionary interventional approach. For example, the latest milestone research has revealed how interindividual variations in intestinal microbiome may play a pivotal role in the observed heterogeneity of the response to immune-checkpoint inhibitors. This Special Issue, entitled “Signaling Pathways and Immune-Checkpoint Regulation in Cancers”, welcomes contributions in the form of original research articles or reviews, aiming to shed light and explore all the novel molecular players involved in the inhibition of both known (e.g., CTLA-4, PD-1/PD-L1) and emerging (e.g., CD47, TIGIT, KIR-L, LAG-3, TIM-3, etc.) immune checkpoints.

Guest Editor

Dr. Silvia Vivarelli

Department of Biomedical and Dental Sciences and Morphofunctional Imaging (BIOMORF), Occupational Medicine Section, University of Messina, Messina, Italy

Deadline for manuscript submissions

closed (15 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/136369

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).